When the Tumor Disappears, Must the Larynx Follow?
REMATCH, a single-institution phase II study, evaluated reduced-volume surgery in patients with locally advanced head and neck cancer responding to neoadjuvant immunochemotherapy. Two-year disease-free survival was 90%, with universal laryngeal preservation. The trial advances organ preservation by reducing the extent and intensity of local therapy rather than substituting modalities.
Authors
- Nadeem Riaz (ORCID: https://orcid.org/0000-0001-9873-5862)
- Achraf A. Shamseddine (ORCID: https://orcid.org/0000-0003-3686-5850)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-10-19
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-2916
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00